Neurizon Therapeutics Limited has released a press release.
Monepantel Principal Metabolite Shows Anti-Cancer Activity
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Develops Method for MPL/Analogue Manufacture
- GMP Tablet Manufacture Commences for Canine Clinical Trials
- Appendix 4C & Company Update - Sep 2018
- PharmAust Develops GMP Method for Monepantel Analogues
- PharmAust Progresses Monepantel Tablet Program for Cancer
Later from Neurizon Therapeutics
- Optimisation of Monepantel Uptake
- PharmAust and Elanco Execute Data Sharing Agreement
- PharmAust Appendix 4C and Shareholders Update
- PharmAust Completes Scaled Manufacture of Monepantel Tablets
- PharmAust Signs Agreement for US Phase I Trials in Dogs
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics